

## Supplemental Online Content

Waks AG, Ogayo ER, Paré L, et al. Assessment of the HER2DX assay in patients with *ERBB2*-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. *JAMA Oncol*. Published online April 27, 2023.  
doi:10.1001/jamaoncol.2023.0181

**eTable 1.** Main patient population of the DAPHNe trial cohort and HER2DX sub-population

**eTable 2.** HER2DX pCR likelihood score and residual cancer burden (RCB) category

**eTable 3.** HER2DX pCR likelihood score and hormone receptor (HR) IHC status

**eFigure.** Consort diagram

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Main patient population of the DAPHNe trial cohort and HER2DX sub-population.

	HER2DX sub-population		Original trial population	
	N	%	N	%
<b>N</b>	80	-	98	-
<b>Age (mean and range)</b>	50.3 (26-78)		49.5 (24-78)	
<b>Clinical tumor stage</b>				
cT1	15	18.7%	18	18.4%
cT2-3	65	81.3%	80	81.6%
<b>Clinical nodal stage</b>				
cN0	52	65.0%	65	66.3%
cN1-3	28	35.0%	33	36.7%
<b>Pathological response (breast and axilla)</b>				
pCR	48	60.0%	55	56.7%
Residual disease	32	40.0%	42	43.3%
<b>Hormone receptor status</b>				
Positive	56	70.0%	65	66.3%
Negative	24	30.0%	33	33.7%

Abbreviations: pCR, pathologic complete response.

eTable 2: HER2DX pCR likelihood score and residual cancer burden (RCB) category.

	RCB-0	RCB-I	RCB-II	RCB-III
HER2DX pCR high (n=27)	25 (92.6%)	1 (3.7%)	1 (3.7%)	0
HER2DX pCR medium (n=22)	14 (63.6%)	3 (13.6%)	5 (22.7%)	0
HER2DX pCR low (n=31)	9 (29.0%)	1 (3.2%)	19 (61.3%)	2 (6.5%)


Abbreviations: RCB, residual cancer burden.

eTable 3. HER2DX pCR likelihood score and hormone receptor (HR) IHC status

<b>HER2DX pCR likelihood score group</b>	<b>HR IHC Status</b>	<b>N (%)</b>	<b>pCR Rate</b>
High	HR+	9 (11.2%)	88.9%
High	HR-	18 (22.5%)	94.4%
Medium	HR+	17 (21.2%)	58.8%
Medium	HR-	5 (6.2%)	80.0%
Low	HR+	30 (37.6%)	30.0%
Low	HR-	1 (1.2%)	0%

Abbreviations: IHC, immunohistochemistry; pCR, pathologic complete response.

eFigure. Consort diagram.



Abbreviations: AC, doxorubicin + cyclophosphamide; Nx, unknown nodal status.